User Fee Revision Reduces Expected CDER Staffing Increases By 139 FTEs
Executive Summary
A revision of FDA's estimated revenues from user fees will reduce the expected additions in staff to the Center for Drug Evaluation & Research to 40% of previous estimates.You may also be interested in...
FDA To Discuss "PDUFA III" Agenda At September Meeting
FDA is soliciting public input into its goals for reauthorization of the Prescription Drug User Fee Act.
FDA To Discuss "PDUFA III" Agenda At September Meeting
FDA is soliciting public input into its goals for reauthorization of the Prescription Drug User Fee Act.
FDA Wants More "Predictable" Revenue Stream Under PDUFA III
FDA would like to ensure a more "predictable" revenue stream under the third Prescription Drug User Fee Act.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: